Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Private Comparative Effectiveness Arbiter Is In Industry’s Interest – Attorney

This article was originally published in The Gray Sheet

Executive Summary

Industry should develop a third-party comparative effectiveness review organization to preclude Congress from creating a similar body, Sidley Austin Brown & Wood partner Patrick Morrisey said Dec. 5

You may also be interested in...



FDA’s Gottlieb: Any FDA/CMS Collaboration Efforts Should Occur Postmarket

FDA and CMS should streamline their internal review processes before pursuing collaborative efforts to avoid an overly burdensome review process, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD

FDA’s Gottlieb: Any FDA/CMS Collaboration Efforts Should Occur Postmarket

FDA and CMS should streamline their internal review processes before pursuing collaborative efforts to avoid an overly burdensome review process, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD

Reimbursement News In Brief

Genzyme keeps separate HCPCS code: Genzyme's Synvisc hyaluronic acid-based product for treating osteoarthritic knee joints will continue to be paid at a higher rate than competing products in 2006, the firm announced Nov. 8. The decision maintains the 2005 rates and reverses CMS' proposal to place all viscosupplement products in the same J-code. Synvisc competes with Johnson & Johnson/Ortho Biotech'sOrthovisc, Sanofi-Aventis' Hyalgan and Smith & Nephew's Supartz (1"The Gray Sheet" June 20, 2005, p. 3). Orthovisc will continue to be paid using miscellaneous codes, according to the firm...

Latest News
See All
UsernamePublicRestriction

Register

MT023010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel